Our study found that the role of miR-29 in non-obese T2DM patients with NAFLD may improve hepatocellular inflammation, uric acid metabolism, and delay the process of atherosclerosis by inhibiting JNK-1. Here, MAPK8 is linked to metabolic dysfunction-associated steatotic liver disease.